| 1351 |
National Cancer Institute |
Html |
en |
Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of osteosarcoma and malignant fibrous histiocytoma of bone. |
| high-grade osteosarcoma patients | 0.629145 |
| co-operative German-Austrian-Swiss osteosarcoma | 0.55607 |
| neoadjuvant cooperative osteosarcoma | 0.624122 |
| pediatric osteosarcoma | 0.57965 |
| locally recurrent osteosarcoma | 0.5543 |
| Primary high-grade osteosarcoma | 0.612176 |
| parosteal osteosarcoma | 0.568181 |
| conventional osteosarcoma | 0.56726 |
| High grade osteosarcoma | 0.599621 |
| cooperative osteosarcoma study | 0.792783 |
| nonmetastatic osteosarcoma | 0.60813 |
| german-austrian-swiss osteosarcoma study | 0.647756 |
| high-grade osteosarcoma | 0.738641 |
| craniofacial osteosarcoma | 0.630712 |
| conventional high-grade osteosarcoma | 0.570688 |
| patients | 0.646684 |
| radiation-associated craniofacial osteosarcoma | 0.580431 |
| European Osteosarcoma Intergroup | 0.58771 |
| osteosarcoma incidence rate | 0.594537 |
| neoadjuvant chemotherapy | 0.670909 |
| high-grade extremity osteosarcoma | 0.5876 |
| Extraskeletal osteosarcoma | 0.568579 |
| Craniofacial osteosarcoma Experience | 0.589537 |
| Group Osteosarcoma Study | 0.569569 |
| radiation-related osteosarcoma | 0.565185 |
|
| osteosarcoma skip metastases | 0.57865 |
| synchronous multifocal osteosarcoma | 0.617106 |
| Osteosarcoma Intergroup study | 0.567726 |
| et al. | 0.76197 |
| PUBMED Abstract | 0.575849 |
| unresectable high-grade osteosarcoma | 0.562489 |
| primary osteosarcoma | 0.586929 |
| periosteal osteosarcoma | 0.560798 |
| osteosarcoma study group | 0.793978 |
| recurrent osteosarcoma | 0.571668 |
| non-metastatic osteosarcoma | 0.633808 |
| multi-institutional osteosarcoma study | 0.604239 |
| extremity osteosarcoma | 0.634474 |
| metastatic osteosarcoma | 0.602383 |
| multiinstitutional osteosarcoma study | 0.587612 |
| Abstract | 0.808529 |
| Clin Oncol | 0.842874 |
| operable osteosarcoma | 0.589711 |
| cooperative german-austrian-swiss osteosarcoma | 0.615008 |
| primary tumor | 0.561916 |
| intermediate-grade osteosarcoma | 0.59029 |
| Oncology Group | 0.566747 |
| cancer | 0.596697 |
| osteosarcoma | 0.959056 |
|
CLICK HERE |
| 1499 |
National Cancer Institute |
Html |
en |
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of paranasal sinus and nasal cavity cancer. |
| hemiparanasal sinus | 0.501642 |
| cure rates | 0.493854 |
| positive nodes | 0.488668 |
| standard treatment schedules | 0.549584 |
| Nodal involvement | 0.497639 |
| cancer deaths | 0.490757 |
| small percentage | 0.485324 |
| paranasal sinuses | 0.76526 |
| operable tumors | 0.521562 |
| PDQ cancer information | 0.674275 |
| (es). | 0.507032 |
| T1 mucosal carcinomas | 0.579667 |
| neck radiation therapy | 0.604078 |
| cancer information summary | 0.645943 |
| frequent type | 0.494315 |
| high doses | 0.481624 |
| Squamous cell carcinoma | 0.582109 |
| breast cancer prevention | 0.543533 |
| direct extension | 0.48751 |
| malignant degeneration | 0.512598 |
| advanced carcinomas | 0.493525 |
| ethmoid sinuses | 0.558752 |
| NCI’s PDQ | 0.512104 |
| NCI PDQ cancer | 0.582736 |
| paranasal sinus cancers | 0.63814 |
|
| radical surgery | 0.487234 |
| frontal sinuses | 0.560784 |
| radiation therapy | 0.931486 |
| low-grade benign tumor | 0.581394 |
| maxillary sinus | 0.511122 |
| locoregional recurrence accounts | 0.563108 |
| nasal vestibule | 0.506572 |
| Lymph nodes | 0.492664 |
| vital areas | 0.483188 |
| distant metastases | 0.516432 |
| bony confines | 0.499241 |
| malignant tumor | 0.600994 |
| PDQ documents | 0.510902 |
| early tumors | 0.514544 |
| radical radiation therapy | 0.591316 |
| advanced disease | 0.493565 |
| nasal cavity | 0.593061 |
| treatment volume | 0.481814 |
| local disease | 0.484616 |
| tumors | 0.539577 |
| stage III tumors | 0.513203 |
| neck cancer | 0.495811 |
| postoperative radiation therapy | 0.591777 |
| adjacent structures. | 0.488857 |
|
CLICK HERE |
| 1561 |
National Cancer Institute |
Html |
en |
Hairy Cell Leukemia Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of hairy cell leukemia. |
| red blood cells | 0.288652 |
| cancer treatment | 0.275128 |
| following PDQ summaries | 0.252637 |
| PDQ cancer information | 0.3118 |
| clinical trial search | 0.280542 |
| white blood cells | 0.33408 |
| clinical trials | 0.546221 |
| mature blood cells | 0.288256 |
| Natural killer cells | 0.259899 |
| bone marrow cell | 0.248193 |
| cancer information summary | 0.285589 |
| clinical trial | 0.391443 |
| patients | 0.269231 |
| blood cells | 0.357276 |
| earlier clinical trials | 0.248664 |
| Biologic therapy | 0.261621 |
| refractory hairy cell | 0.259547 |
| treatment clinical trial | 0.258654 |
| PDQ Adult Treatment | 0.254235 |
| Cell Leukemia Treatment | 0.279873 |
| NCI PDQ cancer | 0.262149 |
| Treatment Editorial Board | 0.264015 |
| treatment | 0.372653 |
| myeloid stem cell | 0.267967 |
|
| blood stem cell | 0.256899 |
| progressive hairy cell | 0.304412 |
| new cancer treatments | 0.249482 |
| NCI-supported cancer | 0.251402 |
| cancer cells | 0.341635 |
| lymphoid stem cell | 0.268394 |
| laboratory test | 0.252149 |
| Cancer Information Service | 0.24796 |
| specific cancer cells | 0.268675 |
| treatment clinical trials | 0.277379 |
| blood stem cells | 0.287064 |
| National Cancer Institute | 0.286081 |
| normal cells | 0.252914 |
| new treatment | 0.277346 |
| hairy cell leukemia | 0.902024 |
| bone marrow | 0.339709 |
| healthy blood cells | 0.262175 |
| untreated hairy cell | 0.280676 |
| cancer clinical trials | 0.292375 |
| cancer information summaries | 0.250228 |
| comprehensive cancer information | 0.249864 |
| cancer | 0.442493 |
| standard treatment | 0.257771 |
| leukemia cells | 0.29846 |
|
CLICK HERE |
| 1599 |
National Cancer Institute |
Html |
en |
Selected Vegetables/Sun's Soup (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of selected vegetables/Sun's soup as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| General Information section | 0.439986 |
| phase I/II | 0.372901 |
| soup | 0.641588 |
| eligible patients | 0.381172 |
| United States | 0.398891 |
| Human/Clinical Studies section | 0.504014 |
| standard laboratory chow | 0.498456 |
| advanced non-small cell | 0.617549 |
| toxicity arm | 0.381025 |
| control group | 0.47167 |
| Sun’s Soup | 0.39938 |
| cell lung cancer. | 0.443882 |
| Soup treatment group. | 0.419226 |
| fed standard laboratory | 0.408383 |
| conventional therapy | 0.380328 |
| Vegetables/Sun’s Soup | 0.633353 |
| dietary supplements | 0.390642 |
| tumor growth | 0.410892 |
| percent body-weight loss | 0.372171 |
| lymph node metastasis | 0.373015 |
| average KPS score | 0.387592 |
| barbat skullcap | 0.397578 |
| cancer information summary | 0.38735 |
| patent document | 0.416332 |
|
| clinical trial | 0.401308 |
| mung bean | 0.484404 |
| barbata D. Don | 0.434127 |
| best supportive care | 0.383219 |
| shiitake mushroom | 0.46504 |
| patients | 0.656235 |
| primary tumor | 0.381698 |
| Selected Vegetables/Sun | 0.926979 |
| Scutellaria barbata D. | 0.437829 |
| KPS score | 0.444385 |
| non-small cell lung | 0.820617 |
| survival arm | 0.438189 |
| Phaseolus radiatus L. | 0.435744 |
| nonconsecutive case series | 0.385568 |
| median survival time | 0.500228 |
| cell lung cancer | 0.65934 |
| study entry | 0.475867 |
| Soup treatment group | 0.54526 |
| radiation therapy | 0.522928 |
| Hedyotis diffusa Willd. | 0.437904 |
| mice fed standard | 0.407302 |
| Soup dietary supplement | 0.400111 |
| I/II clinical trial | 0.398282 |
|
CLICK HERE |
| 1617 |
National Cancer Institute |
Html |
en |
Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms. |
| red blood cells | 0.746761 |
| chronic idiopathic myelofibrosis | 0.40092 |
| cancer treatment | 0.416363 |
| primary myelofibrosis | 0.53957 |
| PDQ cancer information | 0.430215 |
| bone marrow aspiration | 0.385705 |
| clinical trial search | 0.421224 |
| white blood cells | 0.676519 |
| chronic eosinophilic leukemia | 0.451961 |
| blood cells increases | 0.444984 |
| clinical trials | 0.768861 |
| chronic neutrophilic leukemia | 0.40279 |
| mature blood cells | 0.434847 |
| fewer blood cells | 0.406923 |
| cancer information summary | 0.401424 |
| clinical trial | 0.500574 |
| early signs | 0.377313 |
| patients | 0.431687 |
| blood cells | 0.902472 |
| blood vessels | 0.37721 |
| chronic myelogenous leukemia | 0.406738 |
| Treatment Editorial Board | 0.377482 |
| essential thrombocythemia | 0.420345 |
| treatment | 0.55278 |
| stored stem cells | 0.37624 |
|
| immature blood cells | 0.399031 |
| blood stem cell | 0.37725 |
| cancer cells | 0.408902 |
| -fighting blood cells | 0.405086 |
| lymphoid stem cell | 0.374191 |
| specific cancer cells | 0.392312 |
| chronic myeloproliferative neoplasms | 0.69658 |
| signs | 0.38226 |
| polycythemia vera | 0.418683 |
| patient | 0.388228 |
| treatment clinical trials | 0.396123 |
| blood stem cells | 0.497004 |
| National Cancer Institute | 0.457233 |
| routine blood test | 0.45249 |
| new treatment | 0.393316 |
| white blood cell | 0.399685 |
| extra blood cells | 0.469808 |
| bone marrow | 0.605562 |
| PDQ summary | 0.382577 |
| cancer clinical trials | 0.425229 |
| blood clots | 0.392843 |
| cancer | 0.517448 |
| information | 0.439199 |
| Myelogenous Leukemia Treatment | 0.387746 |
|
CLICK HERE |
| 1694 |
National Cancer Institute |
Html |
en |
Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version |
Childhood central nervous system (CNS) germ cell tumors form from germ cells (a type of cell that forms as a fetus develops and later becomes sperm in the testicles or eggs in the ovaries). Learn about the signs, tests to diagnose, and treatment of pediatric germ cell tumors in the brain in this expert-reviewed summary. |
| tumor marker levels | 0.3628 |
| cancer treatment | 0.421684 |
| Cell Tumors Treatment | 0.421872 |
| tumor marker | 0.418943 |
| blood tumor marker | 0.368072 |
| tumor marker tests | 0.401497 |
| germ cell tumor | 0.574325 |
| chemotherapy | 0.377281 |
| following PDQ summaries | 0.365055 |
| PDQ cancer information | 0.426073 |
| clinical trials | 0.64034 |
| Pediatric Treatment Editorial | 0.365107 |
| cancer information summary | 0.398144 |
| clinical trial | 0.507274 |
| childhood cns | 0.519486 |
| tumor markers | 0.382879 |
| CNS germ cell | 0.581589 |
| Extracranial Germ Cell | 0.410121 |
| different types | 0.371541 |
| NCI PDQ cancer | 0.369493 |
| radiation therapy | 0.586685 |
| Treatment Editorial Board | 0.36802 |
| Cord Tumors Treatment | 0.393052 |
| late effects | 0.370411 |
| treatment | 0.581174 |
|
| cancer cells | 0.438925 |
| treatment clinical trial | 0.368062 |
| PDQ Pediatric Treatment | 0.363419 |
| nervous system germ | 0.412082 |
| treatment clinical trials | 0.389618 |
| National Cancer Institute | 0.397655 |
| diagnose childhood CNS | 0.382168 |
| spinal cord | 0.499499 |
| tumor cells | 0.386305 |
| Germ cells tumors | 0.441556 |
| new treatment | 0.423148 |
| high tumor marker | 0.363373 |
| childhood cancer information | 0.366666 |
| external radiation therapy | 0.366121 |
| brain | 0.390174 |
| PDQ summary | 0.396735 |
| germ cell tumors | 0.941151 |
| cells | 0.445231 |
| cancer clinical trials | 0.367524 |
| stem cell rescue | 0.36994 |
| cancer | 0.582086 |
| standard treatment | 0.367712 |
| tumor marker level | 0.399336 |
| spinal cord tumors | 0.390737 |
|
CLICK HERE |
| 3440 |
National Cancer Institute |
Html |
es |
Exámenes de detección del neuroblastoma (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el neuroblastoma. |
| Visuals Online | 0.563675 |
| PDQ Exámenes | 0.77452 |
| Physician Data Query | 0.971175 |
| ecografÃa fetal | 0.642315 |
| prevención revisa | 0.581226 |
| graves riesgos | 0.622769 |
|
| presente sÃntomas | 0.605798 |
| información ayuda | 0.590632 |
| cuáles tipos | 0.60865 |
| National Cancer Institute | 0.613572 |
| siguientes riesgos | 0.582879 |
| Instituto Nacional | 0.71673 |
|
CLICK HERE |
| 3851 |
National Cancer Institute |
Html |
en |
Treating Cancer without Harming the Heart |
Researchers from the fields of oncology and cardiology are working to find ways to prevent, manage, and possibly even reverse the cardiovascular side effects of certain cancer therapies. |
| childhood cancers | 0.722954 |
| cardiovascular changes | 0.633513 |
| cancer treatment-related cardiotoxicity | 0.773654 |
| ischemic heart disease | 0.641571 |
| research | 0.740587 |
| task force | 0.629922 |
| childhood cancer increases | 0.668587 |
| cardiac health | 0.652664 |
| heart problems | 0.663961 |
| heart failure | 0.684862 |
| risk factors | 0.812151 |
| certain cardiac functions | 0.66508 |
| Community Oncology Research | 0.635145 |
| ischemic cardiac disease | 0.673041 |
| breast cancer patients | 0.750275 |
| adult survivors | 0.677672 |
| heart | 0.763054 |
| breast cancer trial | 0.667286 |
| Prevention Trials Research | 0.631942 |
| radiation therapy | 0.716677 |
| childhood cancer | 0.74187 |
| cancer treatments | 0.731665 |
| childhood cancer treatments | 0.686861 |
| study | 0.637136 |
|
| community oncology | 0.686779 |
| cancer treatment—chemotherapy agents | 0.673113 |
| cardiac side effects | 0.698632 |
| Anderson Cancer Center | 0.750363 |
| early cardiac dysfunction | 0.678902 |
| new research strategies | 0.65852 |
| trastuzumab-related cardiac events | 0.724465 |
| Dana-Farber Cancer Institute | 0.652906 |
| Community Oncology Cardiotoxicity | 0.640076 |
| cardiac risk factors | 0.767014 |
| subsequent research agendas | 0.636051 |
| cardiac adverse effects | 0.710556 |
| MD Anderson Cancer | 0.75179 |
| cardiac arrhythmia | 0.64223 |
| NCI Community Oncology | 0.685131 |
| NCI-supported cardiotoxicity studies | 0.649029 |
| breast cancer | 0.957268 |
| treatment-induced cardiac disease | 0.677462 |
| NCI community-based oncology | 0.638369 |
| breast cancer treatments | 0.671567 |
| Vanderbilt-Ingram Cancer Center | 0.655353 |
| cancer clinical trials | 0.814235 |
| underlying cardiovascular risk | 0.658241 |
| cardiovascular problems | 0.640023 |
|
CLICK HERE |
| 4337 |
National Cancer Institute |
Html |
en |
Appetite Loss and Cancer Treatment |
Cancer treatments may lower your appetite. Side effects such as nausea, fatigue, or mouth sores can also making eating difficult. Learn how to eat well to avoid losing weight or becoming dehydrated, so you stay strong during treatment. |
| Care PDQ® summary | 0.905921 |
| questions | 0.493671 |
| liquids | 0.644562 |
| dietitian | 0.466542 |
| short walk | 0.691875 |
| health care team | 0.956003 |
| professional version | 0.683094 |
| variety | 0.451735 |
| causes | 0.450224 |
| nurse | 0.455725 |
| Prepare | 0.451462 |
| dehydration | 0.472596 |
| throat problems | 0.73358 |
| drink choices | 0.682925 |
| vomiting | 0.475861 |
| food tastes | 0.745638 |
| Cancer treatments | 0.729931 |
| cancer patients | 0.671489 |
| supplemental nutrition drinks | 0.886258 |
| weight | 0.457616 |
| large meals | 0.701392 |
| plenty | 0.541422 |
|
| calories | 0.468062 |
| list | 0.493655 |
| eating | 0.456684 |
| steps | 0.457353 |
| people | 0.451814 |
| dangerous condition | 0.706738 |
| small meals | 0.702125 |
| way | 0.460708 |
| nausea | 0.479468 |
| nutritional problems | 0.667746 |
| doctor | 0.457447 |
| symptoms | 0.451468 |
| supplements | 0.451833 |
| Cancer-related fatigue | 0.794241 |
| effects | 0.460377 |
| mouth | 0.464482 |
| vitamins | 0.459091 |
| NCI | 0.456663 |
| high-nutrient foods | 0.702331 |
| appetite | 0.964964 |
| information | 0.45027 |
| nutrient-dense foods | 0.715035 |
|
CLICK HERE |
| 16851 |
National Cancer Institute |
Html |
es |
Sulfato de hidracina (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso del sulfato de hidracina como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Centro Nacional | 0.533358 |
| determinados efectos | 0.530508 |
| New Hampshire Avenue | 0.523784 |
| siguientes aspectos | 0.523737 |
| Drug Administration | 0.514799 |
| patients with weight | 0.533925 |
| NCI Best Case | 0.549835 |
| diagnosed non-small-cell lung | 0.536234 |
| Grosvenor M | 0.517103 |
| datos bibliográficos pubmed | 0.525622 |
| siguientes preguntas | 0.515807 |
| Heber D | 0.517667 |
| siguientes riesgos | 0.519241 |
| Instituto Nacional | 0.7207 |
| Su JQ | 0.518581 |
| Salud Complementaria | 0.556196 |
| Visuals Online | 0.516984 |
| siguientes resultados | 0.521312 |
| curso estudios | 0.529991 |
| complementarias revisa | 0.524603 |
|
| Clin Oncol | 0.521025 |
| Physician Data Query | 0.597613 |
| Goldberg RM | 0.517983 |
| PDQ Sulfato | 0.709455 |
| Estados Unidos | 0.833671 |
| Chlebowski RT | 0.553534 |
| breakdown measured | 0.519564 |
| libre uso | 0.517176 |
| compañÃa farmacéutica | 0.520309 |
| página manejo | 0.515736 |
| ¿El tratamiento | 0.532073 |
| Bulcavage L | 0.518136 |
| patients with | 0.551924 |
| siguientes datos | 0.520348 |
| ¿Los beneficios | 0.514828 |
| juntos cam | 0.514239 |
| Funcionamiento motor | 0.518326 |
| Tayek JA | 0.519355 |
| Series Program | 0.514501 |
| medicina complementaria | 0.982503 |
|
CLICK HERE |